BioNTech said it will close three manufacturing sites in Germany after it failed to find buyers for the facilities, affecting multiple sites including Marburg, Idar-Oberstein, and Tübingen. The company indicated the sites would become idle or underused and cited reduced demand for COVID-19 vaccine capacity. The closures also follow BioNTech’s broader restructuring path after acquisition-related capacity decisions, including its CureVac deal. BioNTech described agreeing socially responsible solutions and severance arrangements with work councils. Separately, Varda Space Industries secured a $251 million Series D to advance pharmaceutical manufacturing in space—an area pitched as a route to production with distinct microgravity advantages. The investment highlights continued capital allocation toward platform manufacturing innovation rather than only late-stage therapeutics.